Background-Cyclooxygenase (COX)-2 contributes to vascular smooth muscle cell (VSMC) proliferation induced by tumor necrosis factor (TNF) and angiotensin II. The present study demonstrates, however, that depending on prevailing conditions, COX-2-derived prostanoids may also inhibit VSMC proliferation. Methods and Results-TNF-␣ stimulated proliferation of VSMCs by shortening the G 1 phase of the cell cycle. This effect was abolished by NS-398, a selective COX-2 inhibitor. Addition of TNF did not affect the protein-to-DNA ratio, measured by flow cytometry, suggesting that TNF does not induce VSMC hypertrophy. Inhibition of nitric oxide synthase (NOS) activity attenuated TNF-mediated increases in prostaglandin (PG) I 2 synthesis, whereas thromboxane (TX) A 2 production and COX-2 protein expression were unaffected. Moreover, inhibition of NOS activity increased TNF-mediated proliferation by Ϸ23%. Thus, NO preferentially stimulates PGI 2 production, suggesting that production of NO by VSMCs challenged with TNF limits the ability of the cytokine to increase proliferation. NO donors increased COX-2 protein expression and PGI 2 synthesis, had no effect on TXA 2 production, and decreased cell numbers by 50%, indicating that expression of COX-2 per se might not be sufficient to support proliferation. The effects of NO donors were prevented when COX-2 activity was inhibited with NS-398.
W e recently demonstrated that a cyclooxygenase (COX)-2-dependent mechanism was required for vascular smooth muscle cell (VSMC) proliferation in response to either tumor necrosis factor (TNF) or angiotensin II (Ang II). 1 This mechanism might contribute to VSMC hyperplasia associated with vascular injury or pathophysiological conditions in which elevated levels of either TNF or Ang II are evident. VSMCs respond to growth factors by several different mechanisms, including hyperplasia, hypertrophy, and apoptosis. Hyperplasia is an important component of hypertension, atherosclerosis, and restenosis. For instance, significant increases in proliferation were observed in the media of blood vessels obtained from animals with chronic hypertension. 2 TNF has been detected in restenotic lesions, intimal VSMCs and plaques of atherosclerotic arteries, and models of transplantation-associated atherosclerosis, and has been associated with VSMC proliferation in a rabbit balloon-injury model. 3, 4 TNF is produced by VSMCs and increases expression of COX-2 and inducible nitric oxide synthase (NOS). 1, 4, 5 COX-2 is the predominant isoform utilized for the synthesis of prostaglandin (PG) I 2 and thromboxane (TX) A 2 in VSMCs challenged with either TNF or Ang II. 1 Increased levels of NO inhibit VSMC proliferation. 6 In macrophages, however, activation of COX-2 by cytokines downregulated NO-mediated apoptosis. 7 In the present study, we demonstrate for the first time that TNF increases VSMC hyperplasia in a COX-2-dependent manner by shortening the G 1 phase of the cell cycle. We also establish the antiproliferative effects of COX-2 activation in the presence of NO, a reflection of the stimulus-dependent dual functionality of COX-2 on VSMC growth.
Methods

Animals
Male Sprague-Dawley rats (Charles River Laboratory, Wilmington, Mass) weighing 100 to 115 g were maintained on standard rat chow (Ralston-Purina Co) and given tap water ad libitum.
Reagents
TNF was purchased from Pepro Tech Inc. NS-398 was purchased from Biomol Research Laboratory. Aminoguanidine (AG), propidium iodide, detanonoate (DN), sodium nitroprusside (SNP), sulforhodamine 101, RNase A, the DNA fluorochrome 4Ј,6diamidino-2-phenylindole (DAPI), and monoclonal anti-␤-actin (clone AC-15) were purchased from Sigma. Papanonoate, monoclonal anti-COX-1 (No. 160110), and polyclonal anti-COX-2 (No. 160126) were purchased from Cayman. 2,3-Diaminonaphthalene was purchased from Molecular Probes, and anti-p27 kip1 (sc-1641) and anti-cyclin D1 (HD11) were purchased from Santa Cruz.
VSMCs From Thoracic Aortas
Cultures of VSMCs were established as previously described. 1
Western Blot Analysis of COX-2, COX-1, p27 kip , Cyclin D1, and ␤-Actin Proteins Expression of COX proteins was determined as previously described. 1 Analyses of cyclin D1 and p27 kip1 were done after cells were lysed in ice-cold RIPA buffer. Lysates were centrifuged at 14 000g and 4°C for 15 minutes, and the supernatant was separated on a sodium dodecyl sulfate-10% polyacrylamide gel.
Enzyme-Linked Immunosorbent Assay
Analysis of 6-keto-PGF 1␣ and TXB 2 levels was performed on cell-free supernatants with commercially available kits (Neogen) as previously described. 1
Nitrite Assay
Quantification of nitrite/nitrate levels was determined by a fluorometric method based on the reaction of nitrite with 2,3diaminonaphthalene to form the fluorescent product 1-(H)-naphthotriazole. 8
Analysis of Cell Numbers
Cells were seeded at 20 000 per well in 96-well plates, left quiescent for 24 hours in Dulbecco's modified Eagle's medium/Ham's F12 medium containing 0.5% fetal bovine serum, and then challenged. Cell number was determined with a proliferation assay (CellTiter), and absorbance was recorded at 490 nm (Promega). Cells were challenged with TNF (1 nmol/L) in presence or absence of serum (0% to 5%) for 48 hours. Cell number, assessed by recording absorbance at 490 nm, was determined by proliferation assay. Data represent meanϮSEM, nϭ3. ***PϽ0.001, serum (0% to 5%) vs TNF. Insert: Protein-to-DNA ratio was determined after treatment with TNF (1 nmol/L) in presence or absence of serum for 20 hours. Data represent meanϮSEM, nϭ3.
Analysis of Cell Cycle
Cell cycle distribution was determined by staining cellular DNA with propidium iodide and measuring the fluorescence intensity by laser scanning cytometry (CompuCyte). 9 In brief, cells were fixed, permeabilized with ethanol, and stained with a solution of propidium iodide (5 g/mL) containing 0.1% RNase A. Cells were illuminated with a 488-nm argon-ion laser; green (530Ϯ20 nm) and red (Ͼ590 nm) fluorescence was measured by separate photomultipliers. At least 2000 cells were measured per sample, and the relative proportion of cells in the G 1 , S, or G 2 /M phases was estimated by deconvolution of the cellular DNA content-frequency histograms. For normalization of cell cycle data, the percentages of cells in the S and G 2 /M phases in the control cells were combined and considered to be 100%; the changes in S and G 2 /M phases in the treated cells were then analyzed as the percent difference compared with control.
Analysis of Cellular Protein-to-DNA Ratio
Cellular DNA and protein contents were determined after the samples were stained with DAPI (1 g/mL) and sulforhodamine 101 (20 g/mL), respectively. Cellular blue (490Ϯ20 nm) and red (Ͼ590 nm) fluorescence was measured with a flow cytometer (EPICS Elite ESP, Beckman-Coulter). Cells (10 000) were measured, and the ratio of intensity of the red fluorescence of sulforhodamine 101 to that of the blue fluorescence of DAPI was calculated to represent the protein-to-DNA ratio.
Statistical Analysis
The differences between control and treated VSMCs were compared by Student's t test and, in instances where multiple comparisons were made, a 1-way ANOVA, followed by a Bonferroni post hoc test; probability values Յ0.05 were considered statistically significant.
Results
TNF Shortens G 1 Phase Duration
TNF increases VSMC proliferation in a COX-2-dependent manner. 1 The effect of TNF on cell cycle distribution was measured by laser scanning cytometry. Treatment of VSMCs for 20 hours with TNF, in the absence of serum, shortened the G 1 phase, which was correlated with a 50% increase in the percentage of cells in the S and G 2 /M phases ( Figure 1 ). Addition of NS-398 did not affect the percentage of unstimulated cells (control) in the S and G 2 /M phases but prevented the effects of TNF on cell cycle progression. The increased percentage of cells in the S and G 2 /M phases preceded TNF-mediated increases in cell number, consistent with the notion that COX-2 induction by TNF contributes to a hyperplastic growth response of VSMCs. Indeed, significant increases in cell numbers were observed 48 hours after VSMCs were exposed to TNF in the absence of serum ( Figure 2 ). It is important to note that TNF increased cell numbers in the absence of serum, suggesting that TNF increases VSMC hyperplasia even in the absence of growth factors that are present in serum ( Figure 2 ). Moreover, proliferation was facilitated by the combination of serum and TNF ( Figure 2 ). Because the growth response of VSMCs to autacoids might include hyperplasia or hypertrophy, the protein-to-DNA ratio was assessed to establish whether there was a hypertrophic response to TNF. The protein-to-DNA ratio did not change after exposure to TNF, suggesting that this cytokine did not induce VSMC hypertrophy (Figure 2 , insert). Collectively, these data indicate that TNF increases VSMC hyperplasia by shortening the G 1 phase in a COX-2-dependent manner.
Effects of TNF on p27 kip1 and Cyclin D1 Expression
Proteins involved in cell cycle regulation might contribute to a COX-2-dependent growth mechanism. An increase in cyclin D1 and a concomitant decrease in p27 kip1 were observed when VSMCs were exposed to TNF for 8 and 24 hours ( Figure 3 ). These data support the observations regarding cell cycle progression and raise the possibility that COX-2 increases VSMC hyperplasia by way of a mechanism that involves cyclin D1, which promotes cell cycle progression in a p27 kip1 -dependent manner.
Regulation of COX-2-Derived Prostanoid Production by TNF-Mediated NO Synthesis
Increases in VSMC PGI 2 and TXA 2 synthesis are COX-2 dependent. 1 Nitrite levels increased Ϸ3.5-fold (control, 5.26Ϯ0.37 versus TNF, 18.33Ϯ0.66 pmol/g protein; PϽ0.001) after treatment with TNF for 24 hours and were abolished by addition of AG (data not shown). Inhibition of NO production had a differential effect on COX-2-derived prostanoid production. The levels of 6-keto-PGF 1␣ increased Ϸ4-fold when VSMCs were challenged with TNF for 24 hours (Figure 4 ). Basal levels of 6-keto-PGF 1␣ were not affected by treatment with AG; however, NOS inhibition at 24 hours was associated with significantly attenuated levels of 6-keto-PGF 1␣ induced by TNF ( Figure 4 ). Challenge with TNF for 24 hours also increased TXB 2 levels; however, pretreatment with AG had no effect on TNF-induced TXB 2 levels (Figure 4 ). Expression of COX-1 and COX-2 proteins was not affected when NO synthesis was inhibited ( Figure 5 ), suggesting that the differential effects of NO might be related to an effect on COX-2 activity and/or terminal prostanoid synthases present in VSMCs. Thus, TNF-mediated increases in COX-2 expression and TXA 2 synthesis occur via an NO-independent mechanism, whereas COX-2-dependent PGI 2 synthesis is NO dependent.
Effects of NO Donors on Prostanoid Production
Addition of papanonoate for 24 hours increased PGI 2 synthesis Ϸ5-fold but had no effect on TXA 2 synthesis ( Figure 6 ). Similar results were obtained when levels were measured after addition of SNP (50 mol/L) for 8 hours, because 6-keto-PGF 1␣ levels increased Ϸ1.7-fold (control, 217Ϯ31 vs 50 mol/L SNP, 387Ϯ83 pg 6-keto PGF 1␣ /g protein; PϽ0.01). In contrast, SNP had no effect on TXA 2 synthesis (control, 13.5Ϯ1.7 vs 50 mol/L SNP, 13Ϯ2.3 pg TXB 2 /g protein; PϾ0.05). These data are in accord with those obtained with TNF and demonstrate that NO donors selectively increase VSMC PGI 2 synthesis.
Functional Implications of COX-2-NO Interactions on VSMC Proliferation
Because AG attenuated TNF-mediated PGI 2 synthesis, we tested the hypothesis that a reduction in the levels of an antiproliferative prostanoid (ie, PGI 2 ) might affect TNFmediated VSMC proliferation. Indeed, the proliferative response to TNF increased by an additional 23% when VSMCs were treated for 48 hours with TNF in the presence of AG (Figure 7) . These data suggest that NO, produced in response to challenge with TNF, opposes TNF-mediated, COX-2dependent proliferation of VSMCs. Addition of DN (1 mmol/L) or SNP (50 mol/L) increased COX-2 protein expression and decreased cell number (Figure 8 ). COX-1 protein expression was not affected, supporting a COX-2dependent regulation of proliferation by NO donors. Moreover, the data are consistent with an antiproliferative effect of NO on VSMCs that is mediated by PGI 2 derived from COX-2. The data also suggest that increased COX-2 expression after challenge with an NO donor is not sufficient to support a proliferative response of VSMCs in the absence of a mitogenic stimulus and/or an increase in TXA 2 synthesis.
Discussion
We demonstrate that TNF induces VSMC hyperplasia by shortening the G 1 phase of the cell cycle in a COX-2dependent manner. The increased percentage of TNF-treated cells in the S and G 2 /M phases was abolished when COX-2 activity was inhibited. Treatment with TNF increased cyclin D1 and decreased p27 kip1 expression, regulators of cell cycle progression. Furthermore, a decreased duration of G 1 preceded the increase in cell numbers observed after treatment with TNF. Thus, progression through the G 1 phase in VSMCs is dependent on TNF-dependent signals, presumably before commitment to entrance into the S phase can be achieved. Although G 1 shortening is COX-2 dependent, elevation of COX-2 expression per se is not sufficient to support VSMC proliferation, because NO donors, which also increase COX-2, caused a decrease in cell number. Because TNFmediated increases in PGI 2 and TXA 2 synthesis are COX-2 dependent, 1 the combination of COX-2-derived TXA 2 synthesis and a TNF-dependent signal might be required for cell cycle progression. In the absence of these signals, vis-à-vis an increase in COX-2 expression and PGI 2 synthesis, a COX-2dependent decrease in VSMC cell number was observed (Figure 9 ). COX-2-dependent increases in PGI 2 synthesis in response to TNF were NO dependent, whereas COX-2dependent increases in TXA 2 synthesis were NO independent. In addition, NO donors increased COX-2, but not COX-1, protein expression and increased PGI 2 synthesis without affecting TXA 2 production. COX-2-dependent proliferation of VSMCs in response to TNF was increased further when NO-mediated increases in PGI 2 synthesis were attenuated after inhibition of NOS activity. These data suggest that the high levels of PGI 2 produced when VSMCs were exposed to TNF act to antagonize the ability of TNF to drive cells through the cell cycle.
TNF-mediated proliferation and migration of VSMCs might contribute importantly to the development and progression of vascular disease. For instance, plasma TNF concentrations have been associated with early atherosclerosis and are correlated with metabolic and cellular changes considered important for vascular remodeling. 10 The presence of TNF also was detected in models of transplantation-associated atherosclerosis and associated with VSMC proliferation. 4 Moreover, inhibition of TNF with a soluble TNF receptor reagent inhibited acute coronary neointimal formation in a model of coronary-graft atherosclerosis. 11 In VSMCs, Ang II is known to induce hypertrophy in the absence of serum and to induce hyperplasia in the presence of serum. We demonstrate that TNF does not induce VSMC hypertrophy in the absence or presence of serum.
The mechanisms by which TNF increases VSMC proliferation are not well understood; however, recent studies indicate that TNF increases expression of early growth-response factor-1 and extracellular signal-regulated kinases 1 and 2, pathways known to participate in growth. 12, 13 We previously demonstrated that mitogen-activated protein kinase inhibition prevented TNF-mediated COX-2 mRNA accumulation and protein expression in VSMCs. 1 Although the exact contribution between proximal (early growth-response factor-1 and extracellular signal-regulated kinases 1 and 2) and distal (COX-2) products of TNF-mediated gene transcription on VSMC proliferation is not clear, these pathways might complement each other.
Previous studies demonstrated that NO modulates the catalytic activities of the ferriheme enzymes prostacyclin synthase and thromboxane synthase. 14 Moreover, NO might favor a molecular process that activates prostacyclin synthase or protects it from "suicide" inactivation. 15, 16 The present study demonstrates that PGI 2 production in VSMCs was partially NO dependent. In addition, NO donors selectively increased PGI 2 synthesis without affecting TXA 2 production. Previous studies have identified PGI 2 as a prostanoid with antiproliferative properties 17 and TXA 2 as a comitogen for VSMCs. 18, 19 Thus, the increased proliferation of VSMCs after NOS inhibition might reflect removal of the antiproliferative effects of PGI 2 . Furthermore, the preferential inhibition of PGI 2 synthesis by AG might have shifted the balance between PGI 2 and TXA 2 toward the growth-promoting actions of TXA 2 . Thus, a balance of PGI 2 and TXA 2 might be critical to VSMC hyperplasia. These data support the finding that the proliferative response of VSMCs to TNF increased when NOS activity was blocked and suggest that NO might be downregulating TNF-mediated VSMC proliferation via a PGI 2 -dependent mechanism. Although most TXA 2 is generated by platelet-derived COX-1 in in vivo balloon-injury models, 20 for example, significant amounts of TXA 2 are produced by VSMCs after appropriate activation of COX-2. 1 Thus, COX-2-derived TXA 2 synthesis in the microenvironment of VSMCs might have effects on cell growth that are independent of TXA 2 present in plasma, which is derived from platelet COX-1. Stimulation of COX-2-mediated TXA 2 or PGI 2 synthesis might promote or inhibit VSMC proliferation, respectively. These opposing actions suggest that coinduction of the COX and NOS systems might limit the extent of cell proliferation or death. For instance, our data indicate that when both systems are activated, inhibition of cytokineinduced NO production attenuates the antiproliferative response of NO in VSMCs.
NO has been shown to affect VSMC growth and apoptosis by several different mechanisms. NO induces apoptosis in several different cell types by increasing expression of p53, Bcl-2, and other proteins, 21 and upregulation of CPP32, a member of the caspase/interleukin-1␤ converting enzyme protease family, has been linked to NO-mediated apoptosis in VSMCs. 22 The significance of these observations is accentuated by the finding that generation of NO, which leads to apoptosis in VSMCs, contributes to the process of vascular remodeling. 23 The interactions of COX and NO pathways in VSMCs might modulate these events. For instance, NO donors have been shown to attenuate cell cycle progression through the S phase by targeting ribonucleotide reductase. 6 Moreover, inhibition of VSMC proliferation in the G 1 phase by cytokine-induced NOS has been shown to be dependent on cGMP-mediated activation of cAMP-dependent protein ki-nase A. 24 This suggests that there is cGMP/cAMPindependent and -dependent regulation of VSMC proliferation in response to NO. PGI 2 has been shown to increase cAMP production in human VSMCs and accordingly, might inhibit cell cycle progression. 25 Such an interaction suggests that in the absence of TNF, COX-2 induction by NO donors increases cAMP levels by a preferential effect on PGI 2 synthesis. However, in the presence of TNF, a COX-2dependent shortening of G 1 results in VSMC proliferation.
VSMC growth might be a pathophysiological response to diseases like hypertension and arteriosclerosis, 26, 27 and NO can influence net effects on proliferation. 28 The role of COX-2 in the dysregulated proliferation of several tumor cell types has recently been demonstrated. 29, 30 Moreover, interactions between COX-2 and NO that affect growth have been noted in chondrocyte cell death leading to osteoarthritis, because selective inhibition of COX-2 by NS-398 blocked SNP-induced chondrocyte apoptosis. 31 Similar interactions might influence the proliferation of VSMCs because inhibition of COX-2 activity prevented NO-mediated cell death. Furthermore, inhibition of NOS activity in the present study enhanced the COX-2-dependent proliferative response to TNF. Such a mechanism might be relevant to the regulation of hyperplasia and apoptosis in diseases such as atherosclerosis and hypertension.
